YUN88562, formerly known as S1p receptor agonist 1, is an S1P receptor agonist found in patent WO 2015039587 A1, compound example 2. Sphingosine 1-phosphate (S1P) inhibits the activation of human platelets caused by collagen through the S1P4 receptor. Through S1PR4 but not S1PR1, S1P blocks the collagen-induced activation of human platelets. YUN88562, without a code name, has CAS#1514888-56-2. It is designated as YUN88562 for convenience in scientific communication, per Hodoodo Chemical Nomenclature.
Physicochemical Properties
| Molecular Formula | C23H24FN3O3 |
| Molecular Weight | 409.4534 |
| Exact Mass | 409.18 |
| Elemental Analysis | C, 67.47; H, 5.91; F, 4.64; N, 10.26; O, 11.72 |
| CAS # | 1514888-56-2 |
| Related CAS # | 1514888-56-2 |
| PubChem CID | 117972004 |
| Appearance | White to off-white solid powder |
| LogP | 2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 30 |
| Complexity | 578 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | YBIFMTGYWXNIRZ-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C23H24FN3O3/c1-14(2)9-15-3-5-16(6-4-15)22-25-21(26-30-22)17-7-8-18(20(24)10-17)11-27-12-19(13-27)23(28)29/h3-8,10,14,19H,9,11-13H2,1-2H3,(H,28,29) |
| Chemical Name | 1-[[2-fluoro-4-[5-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]methyl]azetidine-3-carboxylic acid |
| Synonyms | YUN-88562; S1P-agonist-1; DC10392; Icanbelimod; S1p receptor agonist 1; S1p-receptor-agonist-1; YUN88562; YUN 88562 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | S1P1 internalization ( EC50 = 9.83 nM ) |
| ln Vivo |
Icanbelimod (oral administration; 0.01 mg/kg-1 mg/kg) exhibits activity at all doses; a 50% reduction in peripheral blood lymphocyte count and a decrease in the 1 mg/kg dose can be observed with a mere 0.01 mg/kg dose. Additionally, the amount of peripheral monocytes and other white blood cells in SD rats is not considerably changed by this compound, which is lymphocyte-specific[1]. Icanbelimod (oral administration; 3 mg/kg; 12 days) is has been demonstrated to prevent lymphocyte outflow. Compound 2 effectively inhibits the development of joint swelling and joint structure destruction in the rat model of type II collagen-induced arthritis[1]. Icanbelimod (oral administration; 0.3-1mg/kg; 30 days; once daily) reduces the risk of experimental autoimmune encephalitis (EAE) in a dose-dependent way in a mouse model[1]. |
| Animal Protocol |
Lewis rats 3 mg/kg Oral administration |
| References |
[1]. Immune adjustment compound, use thereof and pharmaceutical composition comprising same. Patent WO2015039587A1. |
Solubility Data
| Solubility (In Vitro) | DMSO: ~6.8 mg/mL (~16.6 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4423 mL | 12.2115 mL | 24.4230 mL | |
| 5 mM | 0.4885 mL | 2.4423 mL | 4.8846 mL | |
| 10 mM | 0.2442 mL | 1.2212 mL | 2.4423 mL |